fludarabine_phosphate: profile and news

[an error occurred while processing this directive]

Other information

Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Pharmacology
Fludarabine is a chemotherapy drug used in the treatment of chronic lymphocytic leukemia. It acts at DNA polymerase alpha, ribonucleotide reductase and DNA primase, results in the inhibition of DNA synthesis, and destroys the cancer cells.

Mechanism Of Action
Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted.

Drug Category
Immunosuppressive Agents; Antimetabolites; Antineoplastic Agents; ATC:L01BB05

Brand Names/Synonyms
FAMP; Fludara; Fludarabine; Fludarabine 5'-Monophosphate; Fludarabine Monophosphate; Fludarabine Phosphate; Fludarabine Phosphate [Usan:Ban]; Fludura

Dosage Forms
TABLET; POWDER FOR SOLUTION; IV Solution

Absorption
Not Available

Interactions
Interactions for Fludarabine:

The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.

Chemical IUPAC Name
[5-(6-amino-2-fluoro-purin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid

Chemical Formula
C10H13FN5O7P

Half Life
20 hours

Drug Type
Approved Drug

# Accession No
APRD00594

CAS Registry Number
75607-67-9